NO20033883L - Heterosykliske derivater for behandling av kreft og andre proliferative sykdommer - Google Patents
Heterosykliske derivater for behandling av kreft og andre proliferative sykdommerInfo
- Publication number
- NO20033883L NO20033883L NO20033883A NO20033883A NO20033883L NO 20033883 L NO20033883 L NO 20033883L NO 20033883 A NO20033883 A NO 20033883A NO 20033883 A NO20033883 A NO 20033883A NO 20033883 L NO20033883 L NO 20033883L
- Authority
- NO
- Norway
- Prior art keywords
- cancer
- treatment
- proliferative diseases
- heterocyclic derivatives
- heterocyclic
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 125000000623 heterocyclic group Chemical group 0.000 title 1
- 230000002062 proliferating effect Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/34—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US27475101P | 2001-03-07 | 2001-03-07 | |
| PCT/US2002/007001 WO2002072009A2 (en) | 2001-03-07 | 2002-03-07 | Heterocyclic derivatives for the treatment of cancer and other proliferative diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20033883D0 NO20033883D0 (no) | 2003-09-02 |
| NO20033883L true NO20033883L (no) | 2003-11-05 |
Family
ID=23049469
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20033883A NO20033883L (no) | 2001-03-07 | 2003-09-02 | Heterosykliske derivater for behandling av kreft og andre proliferative sykdommer |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US7153875B2 (enExample) |
| EP (1) | EP1385465A4 (enExample) |
| JP (1) | JP2005506290A (enExample) |
| AU (1) | AU2002252227A1 (enExample) |
| BR (1) | BR0207846A (enExample) |
| CA (1) | CA2440184A1 (enExample) |
| EA (1) | EA200300982A1 (enExample) |
| IL (1) | IL157740A0 (enExample) |
| MX (1) | MXPA03008117A (enExample) |
| NO (1) | NO20033883L (enExample) |
| PL (1) | PL373912A1 (enExample) |
| WO (1) | WO2002072009A2 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6515003B1 (en) | 1999-08-31 | 2003-02-04 | Maxia Pharmaceuticals, Inc. | Heterocyclic derivatives for the treatment of diabetes and other diseases |
| PL373912A1 (en) | 2001-03-07 | 2005-09-19 | Incyte San Diego, Inc. | Heterocyclic derivatives for the treatment of cancer and other proliferative diseases |
| WO2002072543A2 (en) | 2001-03-08 | 2002-09-19 | Maxia Pharmaceuticals, Inc. | Rxr activating molecules |
| US20030083357A1 (en) * | 2001-08-17 | 2003-05-01 | Magnus Pfahl | Oxime derivatives for the treatment of dyslipidemia and hypercholesteremia |
| WO2003043998A1 (en) * | 2001-11-15 | 2003-05-30 | Incyte San Diego Incorporated | N-substituted heterocycles for the treatment of hypercholesteremia, dyslipidemia and other metabolic disorders, cancer, and other diseases |
| EP1456165A1 (en) | 2001-11-30 | 2004-09-15 | The Burnham Institute | Induction of apoptosis in cancer cells |
| US7196108B2 (en) | 2002-03-08 | 2007-03-27 | Incyte San Diego Inc. | Bicyclic heterocycles for the treatment of diabetes and other diseases |
| US7102000B2 (en) * | 2002-03-08 | 2006-09-05 | Incyte San Diego Inc. | Heterocyclic amide derivatives for the treatment of diabetes and other diseases |
| EP1606285A4 (en) * | 2003-03-27 | 2009-03-18 | Lankenau Inst Medical Res | NEW IDO HEMMER AND APPLICATION PROCEDURES |
| FR2856401B1 (fr) * | 2003-06-20 | 2010-02-12 | Galderma Res & Dev | Nouveaux composes modulateurs des recepteurs de type ppargamma et leur utilisation dans des compositions cosmetiques ou pharmaceutiques |
| DE10351744A1 (de) * | 2003-10-31 | 2005-06-16 | Schering Ag | Thiazolidinone, deren Herstellung und Verwendung als Arzneimittel |
| US7122700B2 (en) | 2004-07-30 | 2006-10-17 | Xerox Corporation | Arylamine processes |
| AU2006233810B2 (en) * | 2005-04-08 | 2011-02-17 | Galderma Research & Development | New method for the preparation of 6-(3-(1-adamantyl)-4-methoxphenyl)-2-naphthoic acid |
| FR2884248B1 (fr) * | 2005-04-08 | 2007-05-18 | Galderma Res & Dev | Nouveau procede de preparation de l'acide 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphtoique |
| KR100814109B1 (ko) * | 2006-01-09 | 2008-03-14 | 한국생명공학연구원 | 로다닌 유도체, 이의 제조방법 및 이를 유효성분으로함유하는 약학적 조성물 |
| CL2007000995A1 (es) * | 2006-04-11 | 2008-06-27 | Smithkline Beecham Corp | Compuestos derivados de tiazolidinadiona; composicion farmaceutica; y uso para tratar uno o mas estados de enfermedad seleccionada entre trastornos autoinmunes, enfermedad inflamatoria, cardiovascular y neurodegenerativa entre otras. |
| US20080255115A1 (en) * | 2007-04-11 | 2008-10-16 | Michael Gerard Darcy | Thiazolidinedione derivatives as pi3 kinase inhibitors |
| US7592342B2 (en) * | 2007-05-10 | 2009-09-22 | Smithkline Beecham Corporation | Quinoxaline derivatives as PI3 kinase inhibitors |
| PE20090717A1 (es) | 2007-05-18 | 2009-07-18 | Smithkline Beecham Corp | Derivados de quinolina como inhibidores de la pi3 quinasa |
| JP2011505341A (ja) * | 2007-11-21 | 2011-02-24 | デコード ジェネティクス イーエイチエフ | 炎症性、心血管およびｃｎｓ障害を治療するビアリールｐｄｅ４抑制剤 |
| WO2009067621A1 (en) | 2007-11-21 | 2009-05-28 | Decode Genetics Ehf | Biaryl pde4 inhibitors for treating pulmonary and cardiovascular disorders |
| CN102558088A (zh) * | 2010-12-31 | 2012-07-11 | 中国科学院上海药物研究所 | 联苯亚甲基-2-硫代-4-噻唑酮类化合物及其制备方法和用途 |
| US20250066347A1 (en) * | 2021-12-21 | 2025-02-27 | Medific, Inc. | Substituted thiazolidinedione derivative compound, and pharmaceutical composition for preventing or treating cancer, comprising same |
| US12115148B1 (en) | 2024-05-10 | 2024-10-15 | Imam Mohammad Ibn Saud Islamic University | 3-(2-(1,3-dioxoisoindolin-2-yl)ethyl)-5-(2-hydroxy-5-nitrobenzylidene)thiazolidine-2,4-dione as a potential antitumor and apoptotic inducer |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4051842A (en) | 1975-09-15 | 1977-10-04 | International Medical Corporation | Electrode and interfacing pad for electrical physiological systems |
| DE2626348C3 (de) | 1976-06-11 | 1980-01-31 | Siemens Ag, 1000 Berlin Und 8000 Muenchen | Implantierbare Dosiereinrichtung |
| JPS5538359A (en) | 1978-09-12 | 1980-03-17 | Hamari Yakuhin Kogyo Kk | Preparation of 2-(3-benzoylphenyl)-propionic acid |
| US4383529A (en) | 1980-11-03 | 1983-05-17 | Wescor, Inc. | Iontophoretic electrode device, method and gel insert |
| IL72684A (en) | 1984-08-14 | 1989-02-28 | Israel State | Pharmaceutical compositions for controlled transdermal delivery of cholinergic or anticholinergic basic drugs |
| US4931279A (en) | 1985-08-16 | 1990-06-05 | Bausch & Lomb Incorporated | Sustained release formulation containing an ion-exchange resin |
| US4713244A (en) | 1985-08-16 | 1987-12-15 | Bausch & Lomb Incorporated | Sustained-release formulation containing an amino acid polymer with a lower alkyl (C1 -C4) polar solvent |
| US4668506A (en) | 1985-08-16 | 1987-05-26 | Bausch & Lomb Incorporated | Sustained-release formulation containing and amino acid polymer |
| CA1325222C (en) | 1985-08-23 | 1993-12-14 | Lederle (Japan), Ltd. | Process for producing 4-biphenylylacetic acid |
| DE3874257T2 (de) | 1987-03-11 | 1993-02-11 | Kanegafuchi Chemical Ind | Hydroxystyren-derivate. |
| FI91869C (fi) * | 1987-03-18 | 1994-08-25 | Tanabe Seiyaku Co | Menetelmä antidiabeettisena aineena käytettävien bensoksatsolijohdannaisten valmistamiseksi |
| US5223522A (en) | 1988-03-08 | 1993-06-29 | Pfizer Inc. | Thiazolidinedione hypoglycemic agents |
| US5330998A (en) | 1988-03-08 | 1994-07-19 | Pfizer Inc. | Thiazolidinedione derivatives as hypoglycemic agents |
| IE940525L (en) | 1988-05-25 | 1989-11-25 | Warner Lambert Co | Known and selected novel arylmethylenyl derivatives of¹thiazolidinones, imidazolidinones and oxazolidinones useful¹as antiallergy agents and antiinflammatory agents |
| FI940306A0 (fi) | 1991-07-22 | 1994-01-21 | Pfizer | Menetelmä kiraalisten tiatsolidiini-2,4-dionijohdannaisten synteesissä tarvittavien välituotteiden valmistamiseksi |
| US5780676A (en) | 1992-04-22 | 1998-07-14 | Ligand Pharmaceuticals Incorporated | Compounds having selective activity for Retinoid X Receptors, and means for modulation of processes mediated by Retinoid X Receptors |
| ATE195716T1 (de) | 1992-04-22 | 2000-09-15 | Ligand Pharm Inc | Retinoid-x rezeptor selektive verbindungen |
| EP0915090A1 (en) | 1992-09-10 | 1999-05-12 | Eli Lilly And Company | Compounds useful as hypoglycemic agents and for treating Alzheimer's disease |
| EP0671005A1 (en) | 1992-11-25 | 1995-09-13 | La Jolla Cancer Research Foundation | Rxr homodimer formation and bridged bicyclic aromatic compounds and their use in modulating gene expression |
| MX9603414A (es) | 1994-02-17 | 1997-03-29 | American Home Prod | Derivados de bifenilo sustituidos como inhibidores de fosfodiesterasa. |
| US5691376A (en) | 1994-02-17 | 1997-11-25 | American Home Products Corporation | Substituted biphenyl derivatives |
| JPH09136877A (ja) | 1995-06-16 | 1997-05-27 | Takeda Chem Ind Ltd | 複素環化合物、その製造法及び用途 |
| AU701790B2 (en) | 1995-07-17 | 1999-02-04 | Centre International De Recherches Dermatologiques Galderma (C.I.R.D. Galderma) | Method for treating cancers using 6-{3-{1-adamantyl}- 4-hydroxyphenyl} |
| CN1196730A (zh) | 1996-06-19 | 1998-10-21 | 雷迪博士研究基金会 | 具有增强的抗糖尿病活性的穴糖酮的新的多晶型形式及其制备方法 |
| CZ3499A3 (cs) | 1996-07-08 | 1999-11-17 | Galderma Research & Development, S. N. C. | Adamantylová sloučenina, její použití a farmaceutický prostředek ji obsahující |
| EP1007038A2 (en) | 1997-08-21 | 2000-06-14 | Takeda Chemical Industries, Ltd. | Anti-inflammatory agent |
| US5972986A (en) | 1997-10-14 | 1999-10-26 | G.D. Searle & Co. | Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia |
| AU1052599A (en) | 1997-11-12 | 1999-05-31 | Institute Of Medicinal Molecular Design. Inc. | Retinoid receptor agonists |
| US6262044B1 (en) | 1998-03-12 | 2001-07-17 | Novo Nordisk A/S | Modulators of protein tyrosine phosphatases (PTPASES) |
| US6331633B1 (en) | 1998-05-08 | 2001-12-18 | Calyx Therapeutics Inc. | Heterocyclic analogs of diphenylethylene compounds |
| KR20010099623A (ko) | 1998-08-21 | 2001-11-09 | 비로파마 인코포레이티드 | 바이러스 감염 및 관련 질병을 치료 또는 예방하는화합물, 조성물 및 방법 |
| AU6330999A (en) | 1998-09-30 | 2000-04-17 | Roche Diagnostics Gmbh | Rhodanine derivatives for the treatment and prevention of metabolic bone disorders |
| WO2000032598A1 (en) | 1998-12-04 | 2000-06-08 | Structural Bioinformatics Inc. | Methods and compositions for treating inflammatory diseases utilizing inhibitors of tumor necrosis factor activity |
| WO2000063196A1 (en) | 1999-04-20 | 2000-10-26 | Novo Nordisk A/S | New compounds, their preparation and use |
| US6462032B1 (en) | 1999-05-04 | 2002-10-08 | Wyeth | Cyclic regimens utilizing indoline derivatives |
| US6515003B1 (en) * | 1999-08-31 | 2003-02-04 | Maxia Pharmaceuticals, Inc. | Heterocyclic derivatives for the treatment of diabetes and other diseases |
| KR100608416B1 (ko) | 1999-11-12 | 2006-08-02 | 후지모토 쿄다이 가부시키가이샤 | 2-(ｎ-시아노이미노)티아졸리딘-4-온 유도체 |
| FR2812876B1 (fr) | 2000-08-08 | 2002-09-27 | Galderma Res & Dev | Nouveaux composes bi-aromatiques activateurs des recepteurs de type ppar-gamma et leur utilisation dans des compositions cosmetiques ou pharmaceutiques |
| PL373912A1 (en) | 2001-03-07 | 2005-09-19 | Incyte San Diego, Inc. | Heterocyclic derivatives for the treatment of cancer and other proliferative diseases |
| WO2002072543A2 (en) | 2001-03-08 | 2002-09-19 | Maxia Pharmaceuticals, Inc. | Rxr activating molecules |
| EP1373240B1 (en) | 2001-03-14 | 2005-06-15 | Eli Lilly And Company | Retinoid x receptor modulators |
| WO2002080935A1 (en) | 2001-04-04 | 2002-10-17 | Ortho Mcneil Pharmaceutical, Inc. | Combination therapy comprising glucose reabsorption inhibitors and retinoid-x receptor modulators |
| US20030083357A1 (en) | 2001-08-17 | 2003-05-01 | Magnus Pfahl | Oxime derivatives for the treatment of dyslipidemia and hypercholesteremia |
| WO2003043998A1 (en) | 2001-11-15 | 2003-05-30 | Incyte San Diego Incorporated | N-substituted heterocycles for the treatment of hypercholesteremia, dyslipidemia and other metabolic disorders, cancer, and other diseases |
| AR037714A1 (es) | 2001-12-06 | 2004-12-01 | Maxia Pharmaceuticals Inc | Derivados de tiazolidinona y oxazolidinona 2-sustituidos para la inhibicion de fosfatasas y el tratamiento de cancer |
| US7196108B2 (en) | 2002-03-08 | 2007-03-27 | Incyte San Diego Inc. | Bicyclic heterocycles for the treatment of diabetes and other diseases |
| US7102000B2 (en) | 2002-03-08 | 2006-09-05 | Incyte San Diego Inc. | Heterocyclic amide derivatives for the treatment of diabetes and other diseases |
| CA2529154C (en) * | 2003-06-20 | 2013-05-07 | Galderma Research & Development, S.N.C. | Novel compounds that modulate ppar.gamma. type receptors, and use thereof in cosmetic or pharmaceutical compositions |
-
2002
- 2002-03-07 PL PL02373912A patent/PL373912A1/xx not_active Application Discontinuation
- 2002-03-07 JP JP2002570969A patent/JP2005506290A/ja active Pending
- 2002-03-07 EP EP02721289A patent/EP1385465A4/en not_active Withdrawn
- 2002-03-07 US US10/094,142 patent/US7153875B2/en not_active Expired - Fee Related
- 2002-03-07 BR BR0207846-5A patent/BR0207846A/pt not_active Application Discontinuation
- 2002-03-07 EA EA200300982A patent/EA200300982A1/ru unknown
- 2002-03-07 CA CA002440184A patent/CA2440184A1/en not_active Abandoned
- 2002-03-07 AU AU2002252227A patent/AU2002252227A1/en not_active Abandoned
- 2002-03-07 MX MXPA03008117A patent/MXPA03008117A/es unknown
- 2002-03-07 WO PCT/US2002/007001 patent/WO2002072009A2/en not_active Ceased
- 2002-03-07 IL IL15774002A patent/IL157740A0/xx unknown
-
2003
- 2003-09-02 NO NO20033883A patent/NO20033883L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EA200300982A1 (ru) | 2004-12-30 |
| US20020143182A1 (en) | 2002-10-03 |
| CA2440184A1 (en) | 2002-09-19 |
| JP2005506290A (ja) | 2005-03-03 |
| US7153875B2 (en) | 2006-12-26 |
| EP1385465A4 (en) | 2005-09-07 |
| BR0207846A (pt) | 2005-09-13 |
| PL373912A1 (en) | 2005-09-19 |
| IL157740A0 (en) | 2004-03-28 |
| EP1385465A2 (en) | 2004-02-04 |
| NO20033883D0 (no) | 2003-09-02 |
| AU2002252227A1 (en) | 2002-09-24 |
| MXPA03008117A (es) | 2004-11-12 |
| WO2002072009A3 (en) | 2003-10-16 |
| WO2002072009A2 (en) | 2002-09-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20033883L (no) | Heterosykliske derivater for behandling av kreft og andre proliferative sykdommer | |
| CY2020005I1 (el) | Παραγωγο ραπαμυκινης για τη θεραπευτικη αντιμετωπιση καρκινου του παγκρεατος | |
| NO20052760D0 (no) | Fremgangsmate for behandling av kreft og beslektede fremgangsmater. | |
| NO20014560L (no) | Quinasoliner og terapautisk anvendelse derav | |
| NO20024610L (no) | Synergistiske metoder og blandinger for behandling av kreft | |
| NO20025792L (no) | Kinazolinderivater for behandling av tumorer | |
| NO20031442L (no) | Morfolin-acetamidderivater for behandling av inflammatoriske sykdommer | |
| NO20015516L (no) | Preparater og anvendelser av ET743 for behandling av kreft | |
| EE200300396A (et) | Epotilooni derivaatide kasutamine refraktaarsete kasvajate raviks | |
| NO20033682D0 (no) | Epothilone-derivater for behandling av refraktor-tumorer | |
| NO20034780D0 (no) | Antiangiogenisk kombinasjonsterapi for behandling av kreft | |
| NO20044475L (no) | 2-(2,6-diklorfenyl)-diarulimidazoler | |
| NO20040516L (no) | Kombinasjonsterapi for behandling av kreft. | |
| NO20040726L (no) | Kombinasjonspreparater av arylsubstituerte propanolaminderivater med andre aktive forbindelser og anvendelse derav. | |
| NO20030748L (no) | Prodruger av betulinsyrederivater for behandlingen av kreft og HIV | |
| IS8125A (is) | Kínasólínafleiður til að meðhöndla krabbamein | |
| NO20024775D0 (no) | Hydroksyfenyl-piperidin-4-yliden-metyl-benzamidderivater til behandling av smerte | |
| NO20020358D0 (no) | Anvendelse av etodolac for behandling av kreft | |
| NO20044250L (no) | Heterocykliske amid-derivativer for behandling av diabetes og andre sykdommer | |
| NO20055307D0 (no) | Substituerte isokromanforbindelser for behandling av metabolske forstyrrelser, kreft og andre sykdommer | |
| NO20024867D0 (no) | Fremgangsmåte og preparat for behandling av kreft ved administrering av apoptoseinduserende kjemoterapeutiske midler | |
| NO20024776D0 (no) | Hydroksyfenyl-piperazinyl-metyl-benzamidderivater til behandling av smerte | |
| NO20024777D0 (no) | Kinolinyl-piperidin-4-yliden-metyl-benzamidderivater til behandling av smerte | |
| NO20033341D0 (no) | Metoder for administrering av epothilone-analoger for behandling av kreft | |
| NO20043693L (no) | Profylaktisk og terapeutisk behandling av infektiose og andre sykdommer med immunoeffektorforbindelser |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |